Genetics of CD33 in Alzheimer’s Disease and Acute Myeloid Leukemia. Hum Mol Genet. 2015 Mar 11, Malik M, Chiles J 3rd, Xi HS, Medway C, Simpson J, Potluri S, Howard D, Liang Y, Paumi CM, Mukherjee S, Crane P, Younkin S, Fardo DW, Estus S.
The CD33 single nucleotide polymorphism (SNP) rs3865444 has been associated with the risk of Alzheimer’s disease (AD). Rs3865444 is in linkage disequilibrium with rs12459419 which has been associated with efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on aCD33 antibody. We seek to evaluate the extent to which CD33 genetics in AD and AML can inform one another and advance human diseasetherapy. We have previously shown that these SNPs are associated with skipping of CD33 exon 2 in brain mRNA. Here, we report that these CD33SNPs are associated with exon 2 skipping in leukocytes from AML patients and with a novel CD33 splice variant that retains CD33 intron 1. Each copy of the minor rs12459419T allele decreases prototypic full-length CD33 expression by about 25% and decreases the AD odds ratio by about 0.10. These results suggest that CD33 antagonists may be useful in reducing AD risk. CD33 inhibitors may include humanized CD33 antibodies such as Lintuzumab which was safe but ineffective in AML clinical trials. Here, we report that Lintuzumab downregulates cell surface CD33 by 80% in phorbol-ester differentiated U937 cells, at concentrations as low as 10 ng/ml. Overall, we propose a model wherein a modest effect on RNA splicing is sufficient to mediate the CD33 association with AD risk and suggest the potential for an anti-CD33 antibody as an AD-relevant pharmacologic agent.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: email@example.com.